Dedicated to your research needs.


Please enter subscribe form shortcode

Photograph of a diverse group of people. This photo was selected because it represents an ideal population of volunteers for clinical trials.

Phase 2 Clinical Trials in Psychedelic Therapies

Phase 2 clinical trials play a crucial role in the development of psychedelic therapies, offering valuable insights into their efficacy and safety. These trials build upon the promising results of Phase 1 trials and aim to refine treatment protocols, evaluate treatment effectiveness, and assess adverse events. In this blog post, we will delve into the purpose and significance of Phase 2 trials in psychedelic therapies, highlighting the importance of patient diversity and the measurement of treatment effectiveness.

Purpose and Significance of Phase II Trials

Phase 2 trials in psychedelic therapies serve as a vital bridge between Phase 1 trials and larger-scale Phase 3 trials. These trials are designed to assess the efficacy and safety of the therapy in a larger cohort of patients, providing more robust data on its potential benefits and risks. Phase 2 trials also help optimize treatment protocols, ensuring that the therapy is administered in the most effective and standardized manner.

Refining the Treatment Protocol

During Phase 2 trials, researchers work to fine-tune the treatment protocol for psychedelic therapies. This involves determining the optimal dosage, treatment frequency, and duration of the therapy. By carefully refining the treatment protocol, researchers aim to maximize the therapeutic benefits while minimizing any potential risks or adverse effects.

Enrolling a Diverse Patient Population

Patient diversity in Phase 2 trials for psychedelic therapies is of utmost importance. By including individuals from diverse backgrounds, ethnicities, and demographics, researchers can better understand the therapy’s effectiveness across different populations. This inclusion also ensures that the therapy is accessible and beneficial to a wider range of individuals, promoting equal opportunities for treatment and reducing healthcare disparities.

In the realm of Phase 2 clinical trials for psychedelic therapies, patient diversity stands as a paramount consideration. The inclusion of individuals from diverse backgrounds, ethnicities, and demographics is not merely a checkbox; it is a cornerstone that holds the key to understanding the true effectiveness and reach of these innovative treatments.

Patient diversity in Phase 2 clinical trials enriches the tapestry of knowledge. It allows researchers to gain profound insights into how psychedelic therapies affect different populations. This comprehensive understanding is essential for tailoring treatments to diverse individuals and improving their outcomes.

Accessible and Equitable Therapies

A lack of diversity impairs progress. Without representation from various groups, there’s a risk of overlooking disparities in treatment responses. Embracing diversity ensures that psychedelic therapies are accessible and beneficial to a wider range of individuals, reducing healthcare disparities and promoting equal opportunities for treatment.

Real-World Applicability

The world is a diverse tapestry of cultures and experiences. Clinical trials that reflect this diversity offer results that are more applicable to real-world scenarios. This helps healthcare providers make informed decisions about how to use psychedelic therapies in their practice.

The Consequences of a Lack of Diversity in Clinical Trials

Excluding diverse populations from Phase 2 clinical trials for psychedelics can hinder progress. It may lead to an incomplete understanding of a therapy’s effectiveness and safety profile. Moreover, it perpetuates healthcare inequalities and limits the potential for broad therapeutic benefits. Below is a list of a few consequences of the lack of diversity in Clinical Trials:

  1. Inaccurate Treatment Efficacy Assessment: Clinical trials that lack diversity may not accurately represent how a drug or therapy works across various racial, ethnic, and demographic groups. This can result in a skewed perception of a treatment’s effectiveness.
  2. Limited Generalizability: Trials with limited diversity may have findings that only apply to a specific group, making it challenging to generalize results to the broader population.
  3. Healthcare Disparities: Lack of diversity in clinical trials can perpetuate healthcare disparities, as certain groups may not benefit from new treatments, leading to unequal access to effective therapies.
  4. Delayed Drug Approvals: Regulatory agencies like the FDA may require additional studies to assess the safety and efficacy of a drug in underrepresented populations, potentially delaying drug approvals.
  5. Unanticipated Side Effects: Some adverse effects may only become apparent in specific population groups, and a lack of diversity in trials could result in these effects going undetected until post-market surveillance.

Measuring Treatment Effectiveness

Accurate measurement of treatment effectiveness is a key component of Phase 2 trials in psychedelic therapies. Researchers employ various validated outcome measures to assess the therapy’s impact on specific mental health conditions, such as depression, anxiety, and PTSD. These measures provide quantitative data that helps determine the therapy’s overall effectiveness and guides further improvements in its implementation. Here are some common parameters measured in Phase II trials for psychedelic therapies:

Primary Efficacy Endpoints

  • Change in Symptom Severity: Researchers assess the reduction in symptom severity, such as depressive symptoms, anxiety levels, or PTSD-related symptoms, using validated scales like the Hamilton Rating Scale for Depression (HAM-D), Hamilton Anxiety Rating Scale (HAM-A), or Clinician-Administered PTSD Scale (CAPS).
  • Response Rate: The proportion of participants who achieve a predefined level of improvement in symptom severity, often expressed as a percentage.
  • Remission Rate: The proportion of participants who no longer meet the diagnostic criteria for the specific mental health condition.

Secondary Efficacy Endpoints

  • Quality of Life: Researchers measure improvements in the participants’ overall quality of life using validated quality-of-life questionnaires.
  • Functional Impairment: Assessments of the participant’s ability to carry out daily activities and engage in social interactions may be included.
  • Duration of Response: The length of time participants experience symptom relief or improvement after treatment.
  • Patient-Reported Outcomes: Self-reported assessments by participants, including subjective well-being, mood, and treatment satisfaction.

Psychological Assessments

Psychedelic Experience Rating Scales: Specific scales designed to measure the intensity and nature of the psychedelic experience, which can provide insights into its potential therapeutic mechanisms.

Safety and Tolerability

  • Adverse Events: Monitoring and reporting of adverse events and their severity, including any psychological or physiological discomfort during or after the therapy session.
  • Vital Signs: Regular measurements of vital signs like blood pressure, heart rate, and temperature to ensure participant safety.


Biomarker Assessments: Evaluation of specific biological markers in blood, urine, or other bodily fluids that may provide insights into treatment response.

Long-Term Follow-Up

Maintenance of Efficacy: Assessment of whether treatment benefits are sustained over time.

Exploratory Measures (if applicable)

  • Neuroimaging: Brain imaging techniques like fMRI or PET scans may be used to explore changes in brain activity and connectivity associated with treatment.
  • Cognitive Assessments: Evaluation of cognitive function and changes in cognitive processes.
  • Subgroup Analyses: Exploratory analyses to assess whether treatment effects vary among different demographic or clinical subgroups.

These parameters collectively provide a comprehensive evaluation of the efficacy, safety, and impact of psychedelic therapies in Phase II clinical trials, helping researchers determine the treatment’s potential benefits for individuals with mental health conditions.

Addressing Adverse Events

While psychedelic therapies have shown promising results, it is essential to address any potential adverse events during Phase 2 trials. Rigorous monitoring and reporting of adverse events allow researchers to identify and mitigate any risks associated with the therapy. This ensures participant safety and contributes to the development of safe and effective treatment protocols.

Key Takeaways for Phase II Clinical Trials for Psychedelic Therapies

Phase 2 clinical trials in psychedelic therapies serve as a critical step towards advancing these innovative treatments. By refining treatment protocols, enrolling diverse patient populations, measuring treatment effectiveness, and addressing adverse events, these trials provide valuable data that contributes to the development of safe and effective therapies. Patient diversity and accurate measurement of treatment outcomes are key components in ensuring equitable access to psychedelic therapies and improving mental healthcare for all.

Learn More About the Drug Discovery to Market Journey for Psychedelics

  1. FDA Market Approval Process for Psychedelic Therapies
  2. Unveiling the Mysteries: Drug Discovery in Psychedelic Therapies
  3. Building the Foundation: Preclinical Research in Psychedelic Therapies
  4. Navigating the Regulatory Landscape: IND Application for Psychedelic Therapies
  5. First Steps Towards Healing: Phase 1 Clinical Trials in Psychedelic Therapies
  6. Evaluating Efficacy: Phase 2 Clinical Trials in Psychedelic Therapies
  7. The Final Hurdle: Phase 3 Clinical Trials in Psychedelic Therapies

Contact our team to learn more about our psychedelics CRO services for the preclinical phase of drug development.


  1. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443.
  2. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402-1411. doi:10.1056/NEJMoa2032994.
  3. Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019;236(9):2735-2745. doi:10.1007/s00213-019-05249-5.